Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Nature Medicine

Volumn 13, Issue 9, 2007, Pages 1050-1059

  Apetoh, Lionel ^a,b,c   Ghiringhelli, François ^a,b,c,d   Tesniere, Antoine ^a,b,c   Obeid, Michel ^a,b,c   Ortiz, Carla ^a,b,c   Criollo, Alfredo ^a,b,c   Mignot, Grégoire ^a,b,c   Maiuri, M Chiara ^a,b,c,e   Ullrich, Evelyn ^a,b,c   Saulnier, Patrick ^d   Yang, Huan ^f   Amigorena, Sebastian ^c   Ryffel, Bernard ^g   Barrat, Franck J ^h   Saftig, Paul ⁱ   Levi, Francis ^b,j   Lidereau, Rosette ^k   Nogues, Catherine ^k   Mira, Jean Paul ^c   Chompret, Agnès ^d   Joulin, Virginie ^l   Clavel Chapelon, Françoise ^c   Bourhis, Jean ^d   André, Fabrice ^d   Delaloge, Suzette ^d   Tursz, Thomas ^c,d   Kroemer, Guido ^a,b,c   Zitvogel, Laurence ^a,b,c,d   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d IGR   (France)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g CNRS   (France)

^h Dynavax Technologies Corporation   (United States)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j HÔPITAL PAUL BROUSSE   (France)

^k CENTRE RENÉ HUGUENIN   (France)

^l FRE 2939 Centre National de la Recherche Scientifique   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CHLOROQUINE; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOLOGICAL ADJUVANT; MYELOID DIFFERENTIATION FACTOR 88; OXALIPLATIN; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; OSTEOSARCOMA; PYRIDINES; TOLL-LIKE RECEPTOR 4;

MUS;

EID: 34948820602     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1622     Document Type: Article

References (48)

1. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
2. Albert, M.L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
3. Ronchetti, A. et al. Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells. J. Leukoc. Biol. 66, 247-251 (1999).
4. Gorla, R. et al. Differential priming to programmed cell death of superantigen-reactive lymphocytes of HIV patients. AIDS Res. Hum. Retroviruses 10, 1097-1103 (1994).
5. Winau, F. et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24, 105-117 (2006).
6. Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701 (2005).
7. Gardai, S.J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321-334 (2005).
8. Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54-61 (2007).
9. Medzhitov, R. & Janeway, C.A., Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295-298 (1997).
10. Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145 (2001).
11. + T cells by exogenous cell-associated antigens. Immunity 17, 211-220 (2002).
12. Blander, J.M. & Medzhitov, R. On regulation of phagosome maturation and antigen presentation. Nat. Immunol. 7, 1029-1035 (2006).
13. West, M.A. et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 305, 1153-1157 (2004).
14. + T cell response. Immunity 25, 655-664 (2006).
15. Beutler, B. et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24, 353-389 (2006).
16. Huang, B. et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009-5014 (2005).
17. Barrat, F.J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
18. Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S. & Nakanishi, Y. Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J. Immunol. 172, 2039-2047 (2004).
19. Delamarre, L., Couture, R., Mellman, I. & Trombetta, E.S. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J. Exp. Med. 203, 2049-2055 (2006).
20. Seong, S.Y. & Matzinger, P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469-478 (2004).
21. Jiang, D. et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11, 1173-1179 (2005).
22. Biragyn, A. et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 1025-1029 (2002).
23. Park, J.S. et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290, C917-C924 (2006).
24. Tsung, A. et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201, 1135-1143 (2005).
25. Scaffidi, P., Misteli, T. & Bianchi, M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002).
26. Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251 (1999).
27. Rovere-Querini, P. et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825-830 (2004).
28. Arbour, N.C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25, 187-191 (2000).
29. Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185-192 (2002).
30. Erridge, C., Stewart, J. & Poxton, I.R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J. Exp. Med. 197, 1787-1791 (2003).
31. van der Graaf, C. et al. Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine 30, 264-268 (2005).
32. Cheng, I., Plummer, S.J., Casey, G. & Witte, J.S. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 16, 352-355 (2007).
33. Kurts, C., Miller, J.F., Subramaniam, R.M., Carbone, F.R. & Heath, W.R. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188, 409-414 (1998).
34. Shi, Y. & Rock, K.L. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32, 155-162 (2002).
35. Tabeta, K. et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7, 156-164 (2006).
36. Janssen, E. et al. Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. Immunity 24, 787-799 (2006).
37. Shi, Y., Evans, J.E. & Rock, K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425, 516-521 (2003).
38. la Sala, A. et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J. Immunol. 166, 1611-1617 (2001).
39. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823-835 (2006).
40. Bauer, A.K. et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J. Natl. Cancer Inst. 97, 1778-1781 (2005).
41. Gardella, S. et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001 (2002).
42. Messmer, D. et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307-313 (2004).
43. Dumitriu, I.E., Bianchi, M.E., Bacci, M., Manfredi, A.A. & Rovere-Querini, P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81, 84-91 (2007).
44. Hoshino, K. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162, 3749-3752 (1999).
45. Granda, T.G. et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 86, 999-1005 (2002).
46. Lutz, M.B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77-92 (1999).
47. Porgador, A., Yewdell, J.W., Deng, Y., Bennink, J.R. & Germain, R.N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715-726 (1997).
48. Van Rijn, B.B., Roest, M., Franx, A., Bruinse, H.W. & Voorbij, H.A. Single step high-throughput determination of Toll-like receptor 4 polymorphisms. J. Immunol. Methods 289, 81-87 (2004).